jointly by the WBS, the Welsh Office and the British Bone Marrow Donor Appeal (BBMDA) charity. Funding is now realised through the charges levied for WBMDR services and the continuing support of the BBMDA charity. The panel was also established to provide a local source of HLA matched blood products.
For over 7 years, until June 1996, when the WBMDR joined the World Marrow Donor Association (WMDA) and Bone Marrow Donors Worldwide (BMDW), all donor searches, blood sample and marrow requests were conveyed through the BBMR. Between June 1996 and April 1998 the Registry operated through the BBMR for UK patients but conducted its International activities independently. Since April 1998 the Registry has been fully independent for both its UK and International endeavours.
The Registry sought to develop within a framework of quality standards and regular audit. Prior to the Registry's inauguration in 1988 it was decided that high quality HLA-A, B, DR, DQ typing on modest numbers of panel donors was preferable to inferior typing on countless donors. HLAclass II testing, at donor registration, and high quality typing were both considered vital to ensure the shortest interval between initial donor matching and selected donor workup for transplantation. Changes in typing methodology were only pursued after careful evaluation and administrative change was undertaken to improve the effectiveness of the Registry. Significant WBMDR milestones and its current services are shown in Tables 1 and 2 , respectively.
Accreditation
The WBS 'Donor Centre', Regional Tissue Typing Laboratory and WBMDR are BS EN ISO 9001 Registered. The Laboratory is accredited by both Clinical Pathology Accreditation (UK) Limited and the European Federation for Immunogenetics (EFI).
External and internal quality assurance
The Laboratory participates in all UK National External Quality Assurance Schemes for Histocompatibility and Immunogenetics, the University of California, Los Angeles, Tissue Typing Laboratory Exchanges and the EFI DNA Quality Control Exercises. It also fully complies with the EFI Standards for Internal Quality Assurance.
Bone marrow donors worldwide
Since June 1996 the WBMDR has regularly (currently once a month) sent its donor HLA phenotype file electronically 
Electronic data links
Two electronic data links, the 'European Donor Secretariat' (EDS) 1 system and the more advanced 'European Marrow Donor Information System' (EMDIS) 2 allow registries to conduct donor searches, make, for example, blood sample and bone marrow donation requests, and exchange standard messages, through exclusive e-mail links. The WBMDR operates both the EDS and EMDIS systems.
Bone marrow donor panel

Donor recruitment
All WBMDR panel donors are recruited from WBS volunteer blood donors aged between 18 and 45 years who have given at least one full blood donation. Donors are counselled at the time of panel registration (although in many instances this is provided by written information only), before Confirmatory Typing (CT) sample collection and prior to bone marrow or lymphocyte collection. Counselling prior to cell donation is always undertaken by a qualified nurse/counsellor.
Donor panel members
The active donor panel numbers 21 822 (95.4%) of the 22 864 donors registered and HLA typed since January 1989, to the end of June 1999. Therefore, the known donor attrition rate is 4.6% after 10 years and 6 months. The main causes of donor loss are due to medical reasons (69.7%) and personal request to leave the panel (27.1%) ( Table 3) .
The number of donors presently registered on the bone marrow donor panel currently represents approximately 21% of the WBS's active blood donor panel that are aged up to 45 years. The WBS blood donor catchment area covers all of South Wales and extends northwards to Aberystwyth and Newtown (total population approximately 2.2 million). The majority of donors (91.1%) reside in South Wales while about 4.4% live in Mid and North Wales and 4.5% have their home addresses outside of the Principality (Figure 1 ).
Demographics
The male to female ratio is 1:1.35 and the median donor age is 36 years, with 50.9% of donors aged between 18 and 36 years. However, only 46.9% of panel members are considered as 'young donors', that is aged between 18 and 35 years. Figure 2 shows the distribution of donors' gender with age. ing CMV antibody positivity with increasing age (Figure 3) .
HLA phenotyping
All panel donors have been HLA-A, B, DR and DQ typed. During the first 8 years HLA-A and B typing was performed by classical serology. However, this was replaced (in April 1997) by a PCR-based method using sequence-specific priming (PCR-SSP). HLA-DR and DQ typing had been performed by serology, a method founded on restriction fragment length polymorphism (RFLP) and PCR-SSP, in various combinations. Now all initial HLA-A, B, DRB1/3/4/5, and DQB1 typing is carried out by PCR-SSP essentially at the HLA specificity level, as a minimum. 3, 4 Overall, 96% of the panel are typed to the split specificity level or higher resolution and all have been HLA-DR and DQ typed by DNA-based methods (21% by RFLP (and serology) and 79% by PCR-SSP). HLA-A, B typing by PCR-SSP has been performed on 52.6% of the panel donors.
Donor expanded and confirmatory typing is largely carried out at the allele level, using PCR-SSP and/or sequencebased typing (SBT), and includes HLA-Cw, DRB1/3/4/5, DQA1, DPA1 and DPB1 alleles, as required. The HLA-DR103 specificity (DRB1*0103) was identified from the outset of panel donor typing.
Currently, a minimum of 97% of donors are available for patient searching within 15 working days of HLA typing sample collection.
Novel HLA alleles identified in the Registry's donor population
High quality serological and DNA-based HLA typing has allowed the identification of several new and uncommon alleles in the donor panel. New specificities detected by serology have included: the first HLA-B27 specificity possessing the Bw6 epitope (B2708); [5] [6] [7] HLA-B8Jon, the first HLA-B8 subdivision (B*0802); 8, 9 B44Bo (B*4408) a novel HLA-B44 specificity 10 and A*0224. 11 New and rare variants detected by PCR-SSP include: A*2502, B*3527, B*4703 and B*5002.
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HLA population genetics
To provide information on the extent and nature of HLA polymorphisms in the donor population resident in Wales several population genetics studies have been undertaken. These have included: HLA-A, B, DR and DQ phenotype, gene and haplotype frequencies and two-and three-locus linkage disequilibria testing; analyses involving HLA-Cw, DPB1 and the identification of uncommon DR/DQ haplotypes. 3, [16] [17] [18] [19] [20] [21] In addition, the donor panel has furnished useful information for various HLA and disease susceptibility and other immunogenetic studies. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] Unique HLA phenotypes in the donor panel Although the donor panel was still relatively small it was considered important to examine the extent to which unique phenotypes were being added to the panel. The findings could, for example, have consequences for future HLA typing and donor recruitment strategies.
Analysis of 21 363 donor HLA-A, B, DR, DQ phenotypes, all assigned to the same split specificity level, 3 showed that 12 029 (56.3%) occurred once only, ie they were unique. The number of unique phenotypes dropped to 10 983 (51.4%) when HLA-A, B and DR only were considered. Figure 4 shows how the frequency of unique phenotypes decreased with increasing panel size.
The number of unique HLA-A, B, DR phenotypes contributed to the whole panel on a monthly basis was calculated as a percentage of the new donor phenotypes added during that month. Extrapolation of this information suggested that even when the panel contains twice the current number of donors, at least 30% of new donors added would each have unique HLA-A, B, DR phenotypes ( Figure 5 ). Since many transplant units are now requiring allele level recipient/donor matching (at least for HLA-DRB1) these 
Service activities
These are based on the 15 months from operating as an independent registry for UK patients and 36 months from joining BMDW for overseas patients; all data to the end of June 1999.
Donor search requests for UK and overseas patients
The average number of preliminary search requests (facsimile, EDS and EMDIS derived) was 64 and 285 per month for UK and international patients, respectively. Automatic EMDIS searches accounted for approximately 45% of those from overseas. This involved regular search requests from registries in Belgium, France, Germany and Spain. From an analysis of 3472 search requests received by WBMDR an average of 3.5 'exact' matching donors (identical at the split specificity level) was identified for 12.4% of patients. An average of 5.9 'minor' mismatched donors (disparate for one or more splits of HLA-A, B, DR broad specificities) was identified for a further 15.9% of patients.
775 Table 4 Failure to obtain CT samples (based on 763 requests over 3 years with a procurement rate of 82.3%) 
Provision of confirmatory typing samples
During the Registry's lifetime it has received 1436 requests to provide CT samples, of which 1063 have been fulfilled, representing an overall procurement rate of 74.0%. Over the 15 and 36 month periods average monthly CT sample requests were 10 and 9, for UK and overseas patients, respectively. The success rate at obtaining samples was 82%, of which 83% were secured within 14 days of request.
Reasons for failure to obtain CT samples are shown in Table 4 .
Expanded typing service
The WBMDR holds material, DNA and/or cryopreserved whole blood/mononuclear cells, on over 97% of its donors. This allows the rapid expansion, by WBMDR, of the basic specificity level donor HLA-A, B, DR, DQ type, normally within 3 working days of request. This service was typically used for HLA-DRB1*04 allele level donor typing. Over the 15 and 36 month period an average of five and 10 expanded typing service requests were received from the UK and overseas, respectively. All of these were fulfilled and 91.0% of typing reports were faxed to centres within 3 working days of receipt of the request.
Provision of bone marrow and lymphocyte donations
The WBMDR has provided 174 marrow donations, 140 for UK (first donation September 1989) and 34 for overseas patients (first donation January 1997) and 11 lymphocyte donations (nine UK and two overseas) since its inception in 1989. Overseas provision has involved 11 different European countries, the United States of America and Canada. 38 
Performance indicators
A useful overall performance measure of a Registry's quality is the ratio of CT samples requested to the number of bone marrow donations provided. This ratio for the last 36 months was 1:6.3 and 1:9.4, for UK and overseas provision, respectively. The overall ratio, for this period was 1:7.3.
A further practical ratio is that of CT samples provided to bone marrow donations supplied. This relationship helps to give the transplant centre an indication of the likelihood of the donor being tested at the CT sample stage being the required bone marrow donor. This overall ratio was 1:6.0 for the last 36 month period.
Additional performance indicators used by WBMDR, their current target values and attainment levels (for the year ending June 1999) are shown in Table 5 .
Comparisons with other registries
Of 42 non-cord blood panels (BMDW Edition 48) the WBMDR ranked 19th for total panel size, 13th for HLA-A, B, DR typed subjects and 5th for DNA (HLA-DR) typed donors.
For the provision of bone marrow donations during 1998 (WMDA Donor Registries Annual Report-2nd Edition 1998) the WBMDR ranked 11th for total bone marrow donation provision and 13th for the International provision of bone marrow donations.
Future endeavours
In view of the emerging importance of HLA-C and HA-1 in bone marrow transplantation [39] [40] [41] [42] [43] and, for HLA-C, at the request of users, the WBMDR is currently considering donor HLA-C and HA-1 typing at panel registration. Similarly, work is progressing on HLA-A, B allele level typing and HA-1 typing as a development of the Expanded Typing service. In addition, at the request of users, the Registry is examining the possibility of providing G-CSF stimulated peripheral blood stem cells in the near future.
